On November 6, 2025 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, reported that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to add to our body of clinical evidence. At SABCS 2025, we look forward to four poster presentations highlighting findings from studies evaluating the use of (Z)-endoxifen to advance breast cancer treatment and prevention," said Dr. Steven Quay, Atossa Therapeutics President and Chief Executive Officer.

Poster Presentation Details:

Title:

Initial results from RECAST DCIS: Multicenter platform trial testing active
surveillance and novel endocrine therapy agents for DCIS management

Date/Time:

Thursday, December 11, 2025, 12:30pm – 2:00pm CT

Title:

Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot

Date/Time:

Thursday, December 11, 2025, 12:30pm – 2:00pm CT

Title:

(Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants via
Inactive Conformation Stabilization and Reversal of Mutant ESR1-Associated
Transcriptional Signatures

Date/Time:

Friday, December 12, 2025, 7:00am – 8:30am CT

Title:

A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment for
Premenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE)

Date/Time:

Friday, December 12, 2025, 12:30pm – 2:00pm CT

(Press release, Atossa Therapeutics, NOV 6, 2025, View Source [SID1234659613])